Charles Ronan, OD
Optometrist · Tahlequah, OKNPI 1639696057
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $38.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- NEW World Medical,inc.$1K
- Glaukos Corporation$895
- Bausch & Lomb, A Division Of Bausch Health US, LLC$584
- Harrow Eye, LLC$574
- Bausch & Lomb Americas Inc.$514
- plus $4K from 20 others
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$9,123100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 33 | $1,262 |
| NEW World Medical,inc. | 12 | $1,047 |
| Glaukos Corporation | 12 | $895 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $584 |
| Harrow Eye, LLC | 17 | $574 |
| Bausch & Lomb Americas Inc. | 16 | $514 |
| Tarsus Pharmaceuticals, Inc. | 11 | $453 |
| AbbVie(2 entities) | 22 | $447 |
| Dompe US, Inc. | 8 | $446 |
| Rxsight Inc | 11 | $386 |
| Novartis | 21 | $369 |
| Eyevance Pharmaceuticals LLC | 4 | $256 |
| Kala Pharmaceuticals, Inc. | 4 | $253 |
| Biotissue Holdings Inc. | 2 | $227 |
| Ocular Therapeutix, Inc. | 7 | $203 |
| Shire North American Group Inc | 6 | $194 |
| Sight Sciences, Inc. | 6 | $192 |
| The Cameron-ehlen Group, Inc. | 2 | $153 |
| Ivantis, Inc | 1 | $137 |
| Sun Pharmaceutical Industries Inc. | 3 | $136 |
| ANI Pharmaceuticals, Inc. | 4 | $135 |
| Oyster Point Pharma, Inc. | 4 | $135 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $53 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$672
- Ahmed Glaucoma Valve$672
- KXL System$378
- Photrexa$378
- XIIDRA$367
- Streamline Surgical System$348
- Clearpath$324
- Streamline$324
- MIEBO$249
- PanOptix$244
- XDEMVY$241
- Oxervate$224
- iStent Infinite$162
- iDoseTR$162
- ACTIVEFOCUS$146
- Hydrus$137
- OMNI(R) SURGICAL SYSTEM (US)$131
- iStent inject W$128
- iStent$125
- INVELTYS$125
How this compares
$9,149 in reported general payments places this provider in the 95th percentile of 714 optometrist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 606 | $18,372 |
| Ketorolac Tromethamine | 680 | $16,428 |
| XiidraLifitegrast | 18 | $10,935 |
| VyzultaLatanoprostene Bunod | 17 | $6,162 |
| Ciprofloxacin Hcl | 519 | $6,129 |
| LumiganBimatoprost | 11 | $5,652 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,842 |
| ValacyclovirValacyclovir Hcl | 43 | $1,380 |
| MoxifloxacinMoxifloxacin Hcl | 38 | $942 |
| Latanoprost | 103 | $940 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 11 | $639 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 32 | $560 |
| ErythromycinErythromycin Base | 40 | $455 |
| Brimonidine Tartrate | 59 | $444 |
| Doxycycline Hyclate | 11 | $198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $514 | $17,09735 claims |
| AbbVieLumigan, Combigan | $447 | $10,49422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 optometrist providers in Oklahoma.
Other optometrist in Tahlequah
- Nathan LighthizerTahlequah$1M
- Jeff MillerTahlequah$67K
- Charles WhittleTahlequah$28K
- Latricia PackTahlequah$25K
- Cindy ShanTahlequah$16K
- Jenna LighthizerTahlequah$14K
- Aubry TackettTahlequah$12K
- Ryan SwindellTahlequah$7K
- Andrea LasbyTahlequah$6K
- Selina McGeeEdmond$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.